DE60007001T2 - Neurotoxine zur behandlung von pankreatischen krankheiten - Google Patents
Neurotoxine zur behandlung von pankreatischen krankheiten Download PDFInfo
- Publication number
- DE60007001T2 DE60007001T2 DE60007001T DE60007001T DE60007001T2 DE 60007001 T2 DE60007001 T2 DE 60007001T2 DE 60007001 T DE60007001 T DE 60007001T DE 60007001 T DE60007001 T DE 60007001T DE 60007001 T2 DE60007001 T2 DE 60007001T2
- Authority
- DE
- Germany
- Prior art keywords
- botulinum toxin
- pancreatic
- neurotoxin
- use according
- secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002581 neurotoxin Substances 0.000 title claims abstract description 79
- 231100000618 neurotoxin Toxicity 0.000 title claims abstract description 79
- 208000016222 Pancreatic disease Diseases 0.000 title claims abstract description 37
- 208000024691 pancreas disease Diseases 0.000 title claims abstract description 31
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 114
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 99
- 101710138657 Neurotoxin Proteins 0.000 claims abstract description 69
- 230000028327 secretion Effects 0.000 claims abstract description 43
- 210000004923 pancreatic tissue Anatomy 0.000 claims abstract description 36
- 230000001713 cholinergic effect Effects 0.000 claims abstract description 27
- 210000000496 pancreas Anatomy 0.000 claims description 53
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 42
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 39
- 206010033645 Pancreatitis Diseases 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 27
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 21
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 230000002124 endocrine Effects 0.000 claims description 14
- 201000008980 hyperinsulinism Diseases 0.000 claims description 14
- 102000051325 Glucagon Human genes 0.000 claims description 13
- 108060003199 Glucagon Proteins 0.000 claims description 13
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 13
- 229960004666 glucagon Drugs 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 210000000653 nervous system Anatomy 0.000 claims description 10
- 108010069038 botulinum toxin type F Proteins 0.000 claims description 8
- 230000003914 insulin secretion Effects 0.000 claims description 8
- 241000193155 Clostridium botulinum Species 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 241001112695 Clostridiales Species 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 4
- 108700017751 botulinum toxin type C Proteins 0.000 claims description 4
- 108010069022 botulinum toxin type D Proteins 0.000 claims description 4
- 241000193171 Clostridium butyricum Species 0.000 claims description 3
- 108010069023 botulinum toxin type E Proteins 0.000 claims description 3
- 108010069071 botulinum toxin type G Proteins 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 230000005021 gait Effects 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 27
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 8
- 210000003020 exocrine pancreas Anatomy 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 54
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 31
- 229940089093 botox Drugs 0.000 description 31
- 108700012359 toxins Proteins 0.000 description 23
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 239000003053 toxin Substances 0.000 description 21
- 231100000765 toxin Toxicity 0.000 description 21
- 210000002569 neuron Anatomy 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 19
- 210000003205 muscle Anatomy 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 15
- 229960004373 acetylcholine Drugs 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 230000002889 sympathetic effect Effects 0.000 description 13
- 102000004142 Trypsin Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000012588 trypsin Substances 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 108090000631 Trypsin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 10
- 208000013016 Hypoglycemia Diseases 0.000 description 10
- 206010033649 Pancreatitis chronic Diseases 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000010255 intramuscular injection Methods 0.000 description 9
- 239000007927 intramuscular injection Substances 0.000 description 9
- 239000002858 neurotransmitter agent Substances 0.000 description 9
- 210000000277 pancreatic duct Anatomy 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 238000002271 resection Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 210000002932 cholinergic neuron Anatomy 0.000 description 7
- 210000001198 duodenum Anatomy 0.000 description 7
- 210000001819 pancreatic juice Anatomy 0.000 description 7
- 230000001734 parasympathetic effect Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010033647 Pancreatitis acute Diseases 0.000 description 6
- 208000005374 Poisoning Diseases 0.000 description 6
- 201000003229 acute pancreatitis Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 239000002917 insecticide Substances 0.000 description 6
- 206010022498 insulinoma Diseases 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 231100000572 poisoning Toxicity 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- 230000002797 proteolythic effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 210000002820 sympathetic nervous system Anatomy 0.000 description 6
- 208000018505 Endocrine pancreatic disease Diseases 0.000 description 5
- 241000239226 Scorpiones Species 0.000 description 5
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 5
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 206010020718 hyperplasia Diseases 0.000 description 5
- 230000002390 hyperplastic effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010062466 Enzyme Precursors Proteins 0.000 description 4
- 102000010911 Enzyme Precursors Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002638 denervation Effects 0.000 description 4
- 229940098753 dysport Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000030214 innervation Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 208000003508 Botulism Diseases 0.000 description 3
- 101800001982 Cholecystokinin Proteins 0.000 description 3
- 102100025841 Cholecystokinin Human genes 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 108010005730 R-SNARE Proteins Proteins 0.000 description 3
- 102000002215 Synaptobrevin Human genes 0.000 description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 description 3
- 229940122618 Trypsin inhibitor Drugs 0.000 description 3
- 108010027252 Trypsinogen Proteins 0.000 description 3
- 102000018690 Trypsinogen Human genes 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 229940107137 cholecystokinin Drugs 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 210000000609 ganglia Anatomy 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 210000000715 neuromuscular junction Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 description 3
- 210000005037 parasympathetic nerve Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 210000003568 synaptosome Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 108010038061 Chymotrypsinogen Proteins 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000225674 Procerus Species 0.000 description 2
- 206010056658 Pseudocyst Diseases 0.000 description 2
- 108010086019 Secretin Proteins 0.000 description 2
- 102100037505 Secretin Human genes 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000864 hyperglycemic agent Substances 0.000 description 2
- 208000033066 hyperinsulinemic hypoglycemia Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 230000002536 noncholinergic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960002101 secretin Drugs 0.000 description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- 208000017612 Acute Hemorrhagic Pancreatitis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 206010049082 Pancreatic mass Diseases 0.000 description 1
- 206010033650 Pancreatitis haemorrhagic Diseases 0.000 description 1
- 206010033654 Pancreatitis necrotising Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
- 102000018692 Sulfonylurea Receptors Human genes 0.000 description 1
- 108010091821 Sulfonylurea Receptors Proteins 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 101710102828 Vesicle-associated protein Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002164 acetylcholinergic effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000011846 endoscopic investigation Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000011532 familial hyperinsulinism Diseases 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000028018 membrane docking Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 208000021262 pancreatic insulin-producing neuroendocrine tumor Diseases 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 210000005034 parasympathetic neuron Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- -1 potassium cations Chemical class 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 238000007464 sphincterotomy Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002782 sympathoadrenal effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US482831 | 2000-01-11 | ||
| US09/482,831 US6143306A (en) | 2000-01-11 | 2000-01-11 | Methods for treating pancreatic disorders |
| PCT/US2000/017652 WO2001051074A1 (en) | 2000-01-11 | 2000-06-27 | Methods for treating pancreatic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60007001D1 DE60007001D1 (de) | 2004-01-15 |
| DE60007001T2 true DE60007001T2 (de) | 2004-09-30 |
Family
ID=23917628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60007001T Expired - Lifetime DE60007001T2 (de) | 2000-01-11 | 2000-06-27 | Neurotoxine zur behandlung von pankreatischen krankheiten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6143306A (enExample) |
| EP (1) | EP1246634B1 (enExample) |
| JP (2) | JP2003519666A (enExample) |
| AT (1) | ATE255418T1 (enExample) |
| AU (1) | AU771186B2 (enExample) |
| BR (1) | BR0016962A (enExample) |
| CA (1) | CA2397030C (enExample) |
| DE (1) | DE60007001T2 (enExample) |
| DK (1) | DK1246634T3 (enExample) |
| ES (1) | ES2209909T3 (enExample) |
| WO (1) | WO2001051074A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US6337075B1 (en) * | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6821520B2 (en) * | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
| US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US20040219619A1 (en) * | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
| US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
| US7691983B2 (en) | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
| JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
| US6984375B2 (en) * | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
| KR20030018827A (ko) * | 2001-08-31 | 2003-03-06 | 서구일 | Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제 |
| US20030100574A1 (en) | 2001-11-15 | 2003-05-29 | Wilson Nestor Antonio Lagos | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies |
| US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US6776991B2 (en) * | 2002-06-26 | 2004-08-17 | Allergan, Inc. | Methods for treating priapism |
| EP1585560A4 (en) * | 2002-07-26 | 2011-03-16 | Mirus Bio Corp | ADMINISTRATION OF MOLECULES AND COMPLEXES TO IN VIVO MAMMAL CELLS |
| US7824693B2 (en) * | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
| US20120114697A1 (en) | 2002-08-19 | 2012-05-10 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| US8071550B2 (en) * | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| ES2381091T3 (es) * | 2003-03-06 | 2012-05-23 | Botulinum Toxin Research Associates, Inc. | Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica |
| US7393538B2 (en) * | 2003-04-25 | 2008-07-01 | Ackerman Alan H | Clostridial toxin treatment for dermatillomania |
| US7422753B2 (en) * | 2003-04-25 | 2008-09-09 | Allergan, Inc. | Methods for treating trichotillomania |
| US7396535B2 (en) * | 2003-04-25 | 2008-07-08 | Ackerman Alan H | Therapy for obsessive compulsive head banging |
| US7393537B2 (en) | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
| US7390496B2 (en) * | 2003-04-25 | 2008-06-24 | Allergan, Inc. | Therapeutic treatments for repetitive hand washing |
| US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| US20050013850A1 (en) * | 2003-07-15 | 2005-01-20 | Caers Jan K. | Device to assist hyperhydrosis therapy |
| US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
| US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
| US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| US20050148935A1 (en) * | 2003-12-29 | 2005-07-07 | Rozalina Dimitrova | Botulinum toxin injection guide |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
| BRPI0510759A (pt) * | 2004-05-07 | 2007-11-20 | Phytotox Ltd | método de facilitar a cura de um ferimento |
| WO2005110418A2 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Transdermal administration of phycotoxins |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| GB2417419A (en) * | 2004-07-12 | 2006-03-01 | Ipsen Ltd | Therapeutic use of Botulinum toxin |
| US20060024794A1 (en) * | 2004-07-30 | 2006-02-02 | Shengwen Li | Novel methods for production of di-chain botulinum toxin |
| JP5089388B2 (ja) | 2004-09-01 | 2012-12-05 | アラーガン、インコーポレイテッド | 分解可能なクロストリジウム毒素 |
| US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
| US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| CA2601577A1 (en) | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
| US20070106338A1 (en) * | 2005-11-10 | 2007-05-10 | Electrocore, Inc. | Direct and Indirect Control of Muscle for the Treatment of Pathologies |
| US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
| US7811586B2 (en) * | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
| US20080092910A1 (en) * | 2006-10-18 | 2008-04-24 | Allergan, Inc. | Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures |
| US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
| WO2009002437A2 (en) * | 2007-06-25 | 2008-12-31 | The Board Of Regents Of The University Of Texas System | Neurotoxin theraphy for postprandial hyperglycemia |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| CN103747796A (zh) | 2011-07-08 | 2014-04-23 | 阿勒根公司 | 用于治疗自主神经系统病症的方法 |
| US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
| AU2012280947B2 (en) | 2011-07-14 | 2016-04-07 | Allergan, Inc. | Methods for treatment of incontinence associated with sexual activity |
| BR112014001066A2 (pt) | 2011-07-20 | 2017-02-21 | Allergan Inc | toxinas botulínicas para uso em um método para tratamento de depósitos adiposos |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| CN107108703B (zh) | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| US20210277071A1 (en) | 2016-09-29 | 2021-09-09 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
| US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
| JP7186228B2 (ja) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | 非細胞毒性プロテアーゼの注入を案内するための超音波の使用 |
| RU2696286C1 (ru) * | 2018-07-23 | 2019-08-01 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Применение физиологического трипептида из глютаминовой кислоты, цистеина и глицина TAD600 для лечения острого небилиарного панкреатита |
| WO2020047159A1 (en) | 2018-08-28 | 2020-03-05 | Ira Sanders | Skin therapeutics |
| GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
| DE102019215585B4 (de) * | 2019-10-10 | 2022-02-17 | KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság | Verfahren zur prävention von strahlenschäden in humanen drüsen |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| CA3154363C (en) | 2019-10-18 | 2024-03-05 | Penland Foundation | Use of a botulinum toxin for treating autism and/or tolerance to narcotics |
| US11738071B2 (en) | 2021-07-12 | 2023-08-29 | Penland Foundation | Treatment of acute and chronic kidney disease |
| US11925677B2 (en) | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| CA2180011C (en) * | 1993-12-28 | 2001-05-15 | K. Roger Aoki | Botulinum toxins for treating sweating |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| ATE239491T1 (de) * | 1995-06-06 | 2003-05-15 | L Bruce Pearce | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
| US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
-
2000
- 2000-01-11 US US09/482,831 patent/US6143306A/en not_active Expired - Lifetime
- 2000-06-27 WO PCT/US2000/017652 patent/WO2001051074A1/en not_active Ceased
- 2000-06-27 AU AU56406/00A patent/AU771186B2/en not_active Ceased
- 2000-06-27 AT AT00941744T patent/ATE255418T1/de active
- 2000-06-27 DK DK00941744T patent/DK1246634T3/da active
- 2000-06-27 CA CA2397030A patent/CA2397030C/en not_active Expired - Fee Related
- 2000-06-27 EP EP00941744A patent/EP1246634B1/en not_active Expired - Lifetime
- 2000-06-27 DE DE60007001T patent/DE60007001T2/de not_active Expired - Lifetime
- 2000-06-27 BR BR0016962-5A patent/BR0016962A/pt not_active Application Discontinuation
- 2000-06-27 JP JP2001551497A patent/JP2003519666A/ja not_active Withdrawn
- 2000-06-27 ES ES00941744T patent/ES2209909T3/es not_active Expired - Lifetime
-
2012
- 2012-01-04 JP JP2012000047A patent/JP2012116839A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1246634A1 (en) | 2002-10-09 |
| DE60007001D1 (de) | 2004-01-15 |
| JP2012116839A (ja) | 2012-06-21 |
| AU5640600A (en) | 2001-07-24 |
| US6143306A (en) | 2000-11-07 |
| ATE255418T1 (de) | 2003-12-15 |
| WO2001051074A1 (en) | 2001-07-19 |
| EP1246634B1 (en) | 2003-12-03 |
| AU771186B2 (en) | 2004-03-18 |
| CA2397030C (en) | 2013-05-07 |
| CA2397030A1 (en) | 2001-07-19 |
| BR0016962A (pt) | 2002-10-15 |
| JP2003519666A (ja) | 2003-06-24 |
| ES2209909T3 (es) | 2004-07-01 |
| DK1246634T3 (da) | 2004-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60007001T2 (de) | Neurotoxine zur behandlung von pankreatischen krankheiten | |
| DE60100473T2 (de) | Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen | |
| DE60128899T2 (de) | Verwendung eines botulinumtoxins zur herstellung eines arzneimittels zur peripheren behandlung von schmerzen, die nicht mit muskelspasmen oder kopfschmerzen in verbindung stehen | |
| US6261572B1 (en) | Method for treating a pancreatic disorder with a neurotoxin | |
| DE60103770T2 (de) | Botulinumtoxin zur behandlung endokriner erkrankungen | |
| JP4851042B2 (ja) | 糖尿病の治療方法 | |
| DE60016794T2 (de) | Intraspinale botulinus-toxin-enthaltende verbindungen zur schmerzbehandlung | |
| DE60310400T2 (de) | Botulinustoxine zur behandlung von priapismus | |
| DE69427869T2 (de) | Botulinumtoxine zur behandlung von hyperhydrosis | |
| DE60312309T2 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| DE60102016T2 (de) | Verfahren zur behandlung von beweggungsstörungen | |
| DE60306505T2 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
| WO2002060474A2 (de) | Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion | |
| DE19813748A1 (de) | Besserung der Dupuytren-Krankheit | |
| WO2002009743A1 (en) | Method for treating a neoplasm | |
| ALPAR | Botulinum toxin and its uses in the treatment of ocular disorders | |
| WO2001045743A2 (de) | Verwendung eines enzyms zur verbesserung der geweberesorption von arzneimitteln | |
| DE69525728T2 (de) | Verminderung des Fettgewebes durch Verwendung von Kollagenase | |
| DE102004055891B4 (de) | Gemische von Schlangengiften zur Krankheitsbekämpfung | |
| DE10144711A1 (de) | Neue Gemische mikrobieller Enzyme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |